Wed, 18 March 2015
A 742% spending surge for hepatitis C, pricey new diabetes medications, and one new drug class that has payers nervous -- all discussed today by healthcare analyst Michael Douglass and healthcare contributor Todd Campbell on today's Industry Focus. |